Back to News & Events

CFB Client Secures $3M Public and Private Investment

Codagenix, Inc., a clinical stage, venture and public-sector-funded small business, announced it has secured an additional $3M in funding in support of its live-attenuated Respiratory Syncytial Virus (RSV) vaccine candidate that was developed in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH.

The public funding to Codagenix is via a Phase II SBIR grant for $1.5M to support the pre-clinical manufacturing of the vaccine candidate. The private funding of $1.5M was provided by TopSpin Partners to support a Phase I trial to demonstrate safety and immunogenicity in aged volunteers. The two funding source were not linked; however, both are dedicated to supporting Codagneix’s RSV vaccine through a Phase I trial. Clinical Trial material of Codagenix RSV Vaccine candidate is currently being manufactured with a Phase I targeted for Q3- or Q4-2018.

“Codagenix is an incredible example of a company rooting in our expanding bioecosystem, growing from a startup out of Stony Brook University into a clinical stage company” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is proud to provide ongoing support for the work they are doing through our various programs including the Applied Research and Development awards and the Long Island Bioscience Hub funding initiatives.

“We are wrapping up a Phase I with our live-attenuated Influenza Vaccine in Q1-2018 and are very much looking forward to adding a second clinical-stage compound to our pipeline with RSV,” stated Codegenix COO J. Robert Coleman. “We are grateful to our investors and partners like the Center for Biotechnology that understand our vision and continually support our development at these early stages. We are demonstrating that our platform provides a rational means to design vaccines against a range targets – yielding candidates suitable for full clinical development.”

Codagenix has raised a total of $10M since 2015 – with its influenza vaccine candidate currently in Phase I and a pre-clinical pipeline that includes Zika, Dengue, and Agricultural targets in addition to RSV.

RSV is a virus that targets newborns and the elderly, with an estimated market size of $2 Billion for a potential RSV vaccine.

About Codagenix Inc.
Codagenix Inc., a biotechnology company on Long Island, New York, is developing live attenuated vaccines using a “disruptive” software-based rational design algorithm that is unlike previous vaccine “platforms”. By leveraging the redundancy in the genetic code (various codons exist at the gene level to encode the same amino acid at the protein level), the Codagenix algorithm re-structures viral genomes into a sub-optimal genetic code. The so-called “deoptimized” viruses have resulted in highly attenuated vaccine strains that are effective at greatly reduced doses, because they present every antigen of the pathogen, while being 100% identical to the target pathogen at the protein level. The Codagenix pipeline of vaccines includes Influenza, respiratory syncytial virus (RSV), Zika, Dengue, foot-and-mouth disease virus (FMDV), pathogenic E. coli, and other pathogens.

Codagenix has also been supported the Center for Biotechnology at Stony brook University which is a New York State Center for Advanced Technology and NIH-designated Research, Evaluation and Commercialization Hub (REACH)

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5031
                    [post_author] => 3
                    [post_date] => 2026-08-10 12:17:19
                    [post_date_gmt] => 2026-08-10 16:17:19
                    [post_content] => 

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3020 [post_author] => 3 [post_date] => 2018-08-13 15:28:55 [post_date_gmt] => 2018-08-13 15:28:55 [post_content] => The Gund-Harrington Initiative for Fighting Blindness announces the call for proposals for the 2019 Gund-Harrington Scholar Award. The Gund-Harrington Scholar Award supports innovative research efforts that could prevent, treat or cure blindness resulting from inherited retinal degenerative diseases. The Gund-Harrington Scholar Award is part of the Gund-Harrington Initiative for Fighting Blindness and sponsored by Foundation Fighting Blindness and Harrington Discovery Institute. Who should apply?
  • U.S and Canadian scientists at accredited academic medical centers, research institutions and universities whose discoveries show promise for translation into novel treatments for inherited retinal degenerative diseases.
  • Multidisciplinary investigators outside the field of retinal disease developing a therapeutic strategy with a potential to benefit inherited retinal degenerative diseases are particularly encouraged to apply.
Multi-Level Support for Award Recipients includes:
  • Funding totaling up to $900,000 over three years based on progress made towards milestones
  • Drug development and project management support
  • Dedicated pharma team for each scholar
  • Clinical development strategy
  • Regulatory guidance
Letters of Intent are now being accepted through midnight on October 12, 2018. Apply Here.  [post_title] => Funding Opportunity: Gund-Harrington Scholar Award for Fighting Blindness [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => funding-opportunity-gund-harrington-scholar-award-for-fighting-blindness [to_ping] => [pinged] => [post_modified] => 2018-08-13 15:28:55 [post_modified_gmt] => 2018-08-13 15:28:55 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3020 [menu_order] => 116 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2180 [post_author] => 3 [post_date] => 2016-05-03 18:24:23 [post_date_gmt] => 2016-05-03 18:24:23 [post_content] => The Center for Biotechnology has announced the recipients of the 2016-2017 Applied Research & Development (ARAD) awards. The ARAD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community and the later-stage commercial development interests of the bioscience industry. The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy. The projects funded include:
  • ICU Temporary Pacemaker - Dr. Wei Lin and Avery Biomedical Device, Inc.
  • Novel Synergistic and Pleiotropic Skin Brightening Agents - Dr. Sanford Simon and Biocogent, LLC
  • Continued In vivo Testing of Vaccine Candidates - Dr. Eckard Wimmer and Cogadenix, Inc.
  • Advanced Fistula-in-Ano Treatment Device - Dr. Tom Zimmerman and Pepper5, Inc.
  • Development of Nanoemulsion-PUFA-taxoids as Tumor-Targeted Chemotherapeutics - Dr. Iwao Ojima and TargaGenix, Inc.
  • Initial Pre-Clinical Safety Assessment of TRB-N0224 - Dr. Lorne Golub and Traverse Biosciences, Inc.
  • Evaluation of a Continuous Visible Light Disinfection System's Ability to Reduce Bioburden and Subsequently the Incidence of Infections and Colonizations in an Active Patient Area - Dr. Annie Rohan and Vital Vio, Inc.
More information about the Applied Research & Development (ARAD) program, as well as all Center for Biotechnology Technology Development programs can be found here. [post_title] => Applied Research and Development Awards Announced [post_excerpt] => The Center for Biotechnology has announced the recipients of the 2016-2017 Applied Research & Development (ARAD) awards. Matching funds have been awarded to seven projects in support of collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => applied-research-and-development-awards-announced [to_ping] => [pinged] => [post_modified] => 2016-05-06 18:19:05 [post_modified_gmt] => 2016-05-06 18:19:05 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2180 [menu_order] => 183 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 5004 [post_author] => 4 [post_date] => 2026-07-06 13:57:19 [post_date_gmt] => 2026-07-06 17:57:19 [post_content] =>

New York State-based Startup companies have the opportunity to compete for a share of up to $420,000 in funding to accelerate the commercialization their innovative technology or product.

As part of the Jeff Lawrence Innovation Fund, FuzeHub will hold its tenth New York State Commercialization Competition on October 27 & 28 at the Buffalo Convention Center during the New York State Innovation Summit.

The FuzeHub Commercialization Competition is intended to help small manufacturing and technology companies further develop their prototype in an effort to pursue additional investment and customers as well as strengthen their “go-to-market” strategies, as they move from new product/production method to marketplace.

Learn more and apply here: https://fuzehub.com/commercialization-competition/

[post_title] => NYS Commercialization Competition - 2026 Applications Open! [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => nys-commercialization-competition-2026-applications-open [to_ping] => [pinged] => [post_modified] => 2026-07-06 13:57:19 [post_modified_gmt] => 2026-07-06 17:57:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5004 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5031 [post_author] => 3 [post_date] => 2026-08-10 12:17:19 [post_date_gmt] => 2026-08-10 16:17:19 [post_content] =>

Attention Stony Brook University Faculy and Staff: Applications for the second cycle of the President’s Fast Impact Fund (FIF) opened August 3, 2026. Open to all Stony Brook faculty and staff, this special initiative supports immediate-impact projects that can be launched quickly and deliver results within six to ten months.

The FIF provides awards of up to $300,000 focused on low‑investment, high‑reward initiatives that create visible, positive change. Examples of projects that would be considered include specialized equipment or technology acquisitions, pilot programs or proof‑of‑concept initiatives, targeted renovations or seed funding, among other opportunities.

All proposals must include a customized, high-level budget and be endorsed by the relevant vice president or dean with authority to implement the project. Applications for the August cycle will be available beginning August 3 with submissions due Friday, August 21 by 5 pm, ET. Please visit the Fast Impact Fund website for additional information and to submit an application.

[post_title] => SBU President’s Fast Impact Fund (FIF) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-presidents-fast-impact-fund-fif [to_ping] => [pinged] => [post_modified] => 2026-08-19 08:30:44 [post_modified_gmt] => 2026-08-19 12:30:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5031 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 284 [max_num_pages] => 95 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

SBU President’s Fast Impact Fund (FIF)

More Information

Funding Opportunity: Gund-Harrington Scholar Award for Fighting Blindness

More Information

Applied Research and Development Awards Announced

More Information

NYS Commercialization Competition – 2026 Applications Open!

More Information